Should You Buy Aurora Cannabis (TSX:ACB) Stock in 2022?

Aurora Cannabis remains a high-risk bet for investors, despite losing 97% in market value due to its weak financials and a competitive market.

| More on:
edit Jars of marijuana

Image source: Getty Images

Shares of marijuana giant Aurora Cannabis (TSX:ACB)(NYSE:ACB) were trading near record highs after Canada legalized pot for recreational use back in late 2018. However, ACB stock is now down 97% from all-time highs, valuing it at a market cap of $1.2 billion.

Aurora Cannabis stock has grossly underperformed the markets in the last three years due to a variety of reasons that include cannibalization from the illegal market, lower-than-expected demand, widening losses, rising inventory levels, overvalued acquisitions, and billion-dollar writedowns.

Let’s see if Aurora Cannabis can stage a comeback this year, or if it will continue to trail the equity market going forward.

The bull case for Aurora Cannabis

Aurora Cannabis has reported operating losses of more than $1 billion in the last three fiscal years. However, over the last few quarters, the company has focused on cost savings to improve the bottom line and reduce cash-burn rates.

In the second quarter of fiscal 2022 (ended in December), Aurora Cannabis reported an adjusted EBITDA loss of $9 million, which was narrower than its loss of $11.5 million in the previous quarter. Aurora Cannabis emphasized it will report a positive adjusted EBITDA in the first half of fiscal 2023.

In addition to reducing costs, Aurora Cannabis has narrowed its product portfolio in the recreational cannabis vertical to focus on higher-margin medical marijuana products. In fiscal Q2 of 2022, Aurora Cannabis reported medical marijuana sales of $45.7 million, accounting for 75% of total revenue. In the year-ago period, these sales accounted for 57% of total revenue.

Aurora Cannabis increased sales from $55 million in fiscal 2018 to $248 million in fiscal 2019. However, in 2021, its top line stood at $245.2 million and is forecast to decline to $236 million in fiscal 2022. After two consecutive years of falling sales, analysts expect revenue to increase by 14% to $270 million in fiscal 2023. Comparatively, its adjusted loss per share might compress from $4.1 in fiscal 2021 to $0.8 in fiscal 2023.

The bear case for ACB stock

Investors remain worried about declining sales and net losses associated with Aurora Cannabis. In the December quarter, its total sales were down 10% year over year at $60 million. While the company enjoyed an early-mover advantage in the medical marijuana market, the entry of new players has resulted in tepid growth.

Further, its consumer cannabis sales plunged by 48% in fiscal Q2 to $14 million. Aurora Cannabis has lost market share rapidly in the recreational cannabis segment, as it did not expand its portfolio of derivatives-based products in the last three years. However, during its recent earnings call, the company stated it plans to introduce a wide range of products targeting the recreational segment.

While Aurora claimed it will reach profitability within the next four years, investors will remain wary of the management’s lofty promises. But it has consistently failed to deliver on multiple profitability targets in the past.

Aurora Cannabis continues to dilute shareholder wealth by raising equity capital and offset its cash burn. If this trend is replicated in 2022, it’s quite possible for ACB stock to trade significantly lower by the end of this year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »